Critical Outcome Technologies Inc. (COTI) is a Canada-based biotechnology company focused on applying its computer-based technology, CHEMSAS, to identify, profile, optimize and select potential new drug candidates at the discovery stage of preclinical drug development. COTI is concentrated on developing drug candidates for the treatment of various cancers, human immunodeficiency virus (HIV), Alzheimer’s disease and multiple sclerosis. Cancer types specifically targeted include small cell lung cancer, adult myelogenous leukemia (AML), ovarian, endometrial, pancreatic, brain, breast and colorectal cancer. COTI-2 is a novel small molecule that acts by inhibiting Akt/PKB (Protein kinase B) phosphorylation that leads to caspase-9 activation in cancer cells. The Company also seeks to leverage CHEMSAS to identify targeted lead candidates of commercial interest to pharmaceutical, biotechnology, research, and academic organizations on a collaborative basis.